Enanta Pharmaceuticals Inc
NASDAQ:ENTA

Watchlist Manager
Enanta Pharmaceuticals Inc Logo
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Watchlist
Price: 5.95 USD -1.65%
Market Cap: 126.9m USD

Intrinsic Value

ENTA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ENTA stock under the Base Case scenario is 17.56 USD. Compared to the current market price of 5.95 USD, Enanta Pharmaceuticals Inc is Undervalued by 66%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ENTA Intrinsic Value
17.56 USD
Undervaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Enanta Pharmaceuticals Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
ENTA
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for ENTA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Enanta Pharmaceuticals Inc
NASDAQ:ENTA
US
Biotechnology
Market Cap
126.1m USD
IPO
Mar 21, 2013
US
Biotechnology
Market Cap
126.1m USD
IPO
Mar 21, 2013
Price
$false
EPS
$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Enanta Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Enanta Pharmaceuticals Inc

Current Assets 268.1m
Cash & Short-Term Investments 216.7m
Receivables 40.2m
Other Current Assets 11.3m
Non-Current Assets 80.5m
PP&E 77m
Other Non-Current Assets 3.5m
Efficiency

Free Cash Flow Analysis
Enanta Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Enanta Pharmaceuticals Inc

Revenue
66.6m USD
Operating Expenses
-176.9m USD
Operating Income
-110.3m USD
Other Expenses
5.4m USD
Net Income
-104.9m USD
Fundamental Scores

ENTA Profitability Score
Profitability Due Diligence

Enanta Pharmaceuticals Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Negative 1-Year Revenue Growth
Negative Revenue Growth Forecast
Negative 3-Years Revenue Growth
14/100
Profitability
Score

Enanta Pharmaceuticals Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

ENTA Solvency Score
Solvency Due Diligence

Enanta Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
50/100
Solvency
Score

Enanta Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ENTA Price Targets Summary
Enanta Pharmaceuticals Inc

Wall Street analysts forecast ENTA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ENTA is 17.17 USD with a low forecast of 8.08 USD and a high forecast of 22.05 USD.

Lowest
Price Target
8.08 USD
36% Upside
Average
Price Target
17.17 USD
189% Upside
Highest
Price Target
22.05 USD
271% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Enanta Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ENTA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ENTA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ENTA stock?

The intrinsic value of one ENTA stock under the Base Case scenario is 17.56 USD.

Is ENTA stock undervalued or overvalued?

Compared to the current market price of 5.95 USD, Enanta Pharmaceuticals Inc is Undervalued by 66%.

Back to Top